Navigation Links
Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
Date:7/8/2008

HAYWARD, Calif., July 8 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today announced the appointment of James Sabry, M.D., Ph.D., as president and chief executive officer. Dr. Sabry has been a strategic advisor and member of the board of directors since March 2008. Dr. Sabry succeeds Dinesh Patel in the position of president and chief executive officer, who will remain as a consultant to the company.

"James brings a wealth of drug discovery, development, and biotechnology management expertise to Arete and already has made significant contributions to the company. We are confident that his exceptional entrepreneurial leadership will guide the company in the years to come as Arete continues to advance its pipeline of innovative compounds through clinical development," said James Topper, M.D., Ph.D., chairman of the board of Arete Therapeutics Inc. "In addition, on behalf of the board of directors, I would like to thank Dinesh Patel for his dedication and commitment to building a successful biotechnology organization while transitioning Arete from a discovery to a clinical stage company."

Dr. Sabry is chairman of the board of directors and former CEO of Cytokinetics, a company he co-founded in August 1997. Prior to co-founding Cytokinetics, he held faculty positions at the University of California, San Francisco and Harvard Medical School. He serves on the board of directors of HopeLab, a not-for-profit organization developing innovative technologies for the management of cancer, obesity and other diseases, is a member of Dean's Council of the Kennedy School of Government at Harvard University and serves on the advisory boards of numerous organizations including the California Institute of Quantitative Biosciences. Dr. Sabry received an M.D. from Queen's University and a Ph.D. in cell biology from the University of California, San Francisco
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Today, world-renowned scientist Dr. J. Craig Venter announced ... Institute (JCVI) became the first in history to synthetically create ... solutions to a host of global challenges, including generating new ... energy sources; producing clean water; and more.   , ...
... WASHINGTON , May 20 ... today reported positive results from its Phase 1 dose ... to patients with metastatic cancer.  The data presented today ... and gene expression, and anti-cancer effects of JX-594 delivered ...
... ... the release of FreezerPro MultiSite, a new addition to FreezerPro product line. FreezerPro ... facilitating IT resources, simplifying administration and providing a centralized repository of laboratory samples and ... ...
Cached Biology Technology:Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 2Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 3Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 2Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 3Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 4RURO Launches FreezerPro MultiSite 2
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... Researchers have made an important breakthrough in the use ... solar cells an innovative technology that could significantly reduce ... The advance was just reported in Current Applied ... University and Yeungnam University in Korea. This is one ...
... who are taking part in a nationwide initiative, Project ... unusually early, perhaps as a result of climate change. ... and foliage, amassing thousands of observations from across the ... changing climate. The project, started as a pilot ...
... of genetic factors in tinnitus is low, according to new ... the first large population-based study to measure the heritability of ... and to what degree it is hereditary. Prevalence of tinnitus ... countries. Tinnitus is a symptom with a variety ...
Cached Biology News:Advance made in thin-film solar cell technology 2Advance made in thin-film solar cell technology 3'10 most wanted' plants inspected for clues to climate change 2'10 most wanted' plants inspected for clues to climate change 3
... Large (Klenow) Fragment, Exonuclease Minus, is a ... 5´→3´ and the 3´→5´ exonuclease activities present ... (1,2). It is used for random primer ... (5). Klenow Fragment, Exonuclease Minus, will leave ...
... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... offers both high-speed and high-volume versatility ... rotor options, making it ideal for a ... Versatility , High-speed (up to 15,000 ... high-volume (4 x 250mL) swinging bucket rotors ...
Biology Products: